Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

摘要: Abstract Seventy-three patients in whom multiple myeloma could be evaluated were treated with a combination drug protocol (M-2), consisting of melphalan, prednisone, cyclophosphamide, vincristine and BCNU (1,3-bis(2-chloroethyl 1)-1-nitrosourea). All classified according to the clinical staging system Salmon Durie; 75 per cent them stage III. Total tumor cell number was calculated method Salmon. A significant objective remission obtained 40 46 (87 cent) previously untreated patients. The median duration response for this group is presently 20+ months. Twenty-seven these responders are still remission. Thirteen 26 (50 responded. With eight remission, 22+ times between first dose an established two three months groups, respectively. more rapid does not appear shorter. rate correlate type immunoglobulin or light chain secreted. One patient, without secretion, has been 45+ months, primary amyloid have failed respond. At point, it appears that survival time M-2 will significantly longer than earlier at center melphalan prednisone alone.